---
layout: default
title: Brivaracetam
description: "Brivaracetam çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 34
evidence_level: L5
indication_count: 10
---

# Brivaracetam

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Brivaracetamï¼šå¾å±€éƒ¨ç™²ç™‡åˆ°è¦–è¦ºæ€§ç™²ç™‡

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Brivaracetam å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Brivaracetam åŸç‚ºæ²»ç™‚å±€éƒ¨ç™²ç™‡ç™¼ä½œçš„ç¬¬ä¸‰ä»£æŠ—ç™²ç™‡è—¥ç‰©ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°è¦–è¦ºæ€§ç™²ç™‡(visual epilepsy)æœ‰æ²»ç™‚æ½›åŠ›ã€‚
</p>


## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | 1å€‹æœˆå¤§ä»¥ä¸Šå±€éƒ¨ç™²ç™‡ç™¼ä½œç—…äººçš„æ²»ç™‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | visual epilepsyã€status epilepticusã€partial epilepsyã€eating seizuresã€orgasm-induced seizuresã€thinking seizuresã€startle epilepsyã€micturation-induced seizuresã€audiogenic seizuresã€beta-ketothiolase deficiency |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.51% |
| è­‰æ“šç­‰ç´š | L3 (è§€å¯Ÿæ€§ç ”ç©¶/å…‰æ•æ„Ÿæ€§ç ”ç©¶) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 3å¼µ |
| å»ºè­°æ±ºç­– | Proceed |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. visual epilepsy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.51%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Brivaracetam æ˜¯ levetiracetam çš„çµæ§‹é¡ä¼¼ç‰©ï¼Œå…·æœ‰ç¨ç‰¹çš„ä½œç”¨æ©Ÿè½‰ï¼š

1. **SV2A é«˜è¦ªå’ŒåŠ›çµåˆ**ï¼šbrivaracetam å°çªè§¸å›Šæ³¡è›‹ç™½ 2A (SV2A) çš„è¦ªå’ŒåŠ›æ˜¯ levetiracetam çš„ 15-30 å€
2. **å¿«é€Ÿè…¦éƒ¨ç©¿é€**ï¼šé«˜è„‚æº¶æ€§ä½¿å…¶èƒ½å¿«é€Ÿé€²å…¥ä¸­æ¨ç¥ç¶“ç³»çµ±
3. **å…‰æ•æ„Ÿæ€§ç™²ç™‡ç ”ç©¶**ï¼šå·²æœ‰è‡¨åºŠç ”ç©¶è­‰å¯¦ brivaracetam èƒ½æŠ‘åˆ¶å…‰åˆºæ¿€èª˜ç™¼çš„è…¦é›»åœ–ç•°å¸¸åæ‡‰ (PPR)
4. **å»£è­œæŠ—ç™²ç™‡æ´»æ€§**ï¼šå‰è‡¨åºŠç ”ç©¶é¡¯ç¤ºå°å¤šç¨®ç™²ç™‡æ¨¡å‹æœ‰æ•ˆ

è¦–è¦ºæ€§ç™²ç™‡èˆ‡å…‰æ•æ„Ÿæ€§ç™²ç™‡ç›¸é—œï¼Œbrivaracetam åœ¨æ­¤é ˜åŸŸå·²æœ‰åˆæ­¥è‡¨åºŠè­‰æ“šæ”¯æŒã€‚

### è‡¨åºŠè©¦é©—

é›–ç„¡ç›´æ¥é‡å°è¦–è¦ºæ€§ç™²ç™‡çš„è‡¨åºŠè©¦é©—ï¼Œä½†ç›¸é—œçš„å…‰æ•æ„Ÿæ€§ç ”ç©¶æä¾›æ”¯æŒè­‰æ“šï¼š

**Phase II å…‰æ•æ„Ÿæ€§æ¨¡å‹ç ”ç©¶ (2007)**
- Kasteleijn-Nolst Trenite ç­‰äººç™¼è¡¨æ–¼ *Neurology*
- è­‰å¯¦ brivaracetam èƒ½æœ‰æ•ˆæŠ‘åˆ¶å…‰åˆºæ¿€èª˜ç™¼çš„ç•°å¸¸è…¦é›»åœ–åæ‡‰
- é¡¯ç¤ºå¿«é€Ÿçš„ä¸­æ¨ç¥ç¶“ç³»çµ±ä½œç”¨

**èˆ‡ Levetiracetam æ¯”è¼ƒç ”ç©¶ (2020)**
- Reed RC ç­‰äººç™¼è¡¨æ–¼ *CNS Drugs*
- é›™ç›²ã€éš¨æ©Ÿã€äº¤å‰è©¦é©—
- è­‰å¯¦ brivaracetam åœ¨å…‰æ•æ„Ÿæ€§ç™²ç™‡æ‚£è€…ä¸­çš„å¿«é€Ÿèµ·æ•ˆæ™‚é–“

### ç›¸é—œæ–‡ç»

PubMed æª¢ç´¢ç™¼ç¾å¤šç¯‡ç›¸é—œæ–‡ç»ï¼š

1. **Klein P, Bourikas D (2024)** - *Advances in Therapy*
   - ç³»çµ±æ€§å›é¡§ brivaracetam çš„å‰è‡¨åºŠèˆ‡è‡¨åºŠæ•ˆç›Š
   - å¼·èª¿å…¶åœ¨é›£æ²»æ€§ç™²ç™‡çš„æ‡‰ç”¨åƒ¹å€¼

2. **Matagne A ç­‰äºº (2008)** - *British Journal of Pharmacology*
   - ç¢ºç«‹ brivaracetam ä½œç‚ºé«˜è¦ªå’ŒåŠ› SV2A é…é«”çš„æŠ—ç™²ç™‡ç‰¹æ€§
   - åœ¨è½æºæ€§ç™²ç™‡ç­‰å¤šç¨®æ¨¡å‹ä¸­å±•ç¾æ´»æ€§

3. **Nicolas JM ç­‰äºº (2016)** - *Epilepsia*
   - è­‰å¯¦ brivaracetam çš„é«˜è…¦éƒ¨ç©¿é€æ€§å’Œå¿«é€Ÿèµ·æ•ˆç‰¹æ€§

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. status epilepticus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.40%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. eating seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. orgasm-induced seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. thinking seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. startle epilepsy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. micturation-induced seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. audiogenic seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. beta-ketothiolase deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.14%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.14%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. adolescent/adult onset autosomal dominant epilepsy with auditory features</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.10%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.10%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
Brivaracetam åœ¨å°ç£çš„è—¥å“è¨±å¯è­‰ï¼š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… |
|-----------|--------|------|-------------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027714è™Ÿ | å¿…æ²»ç™²è†œè¡£éŒ  10mg | è†œè¡£éŒ  | å°ç£å„ªæ™‚æ¯”è²¿æ˜“æœ‰é™å…¬å¸ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027714è™Ÿ | å¿…æ²»ç™²è†œè¡£éŒ  25mg | è†œè¡£éŒ  | å°ç£å„ªæ™‚æ¯”è²¿æ˜“æœ‰é™å…¬å¸ |
| è¡›éƒ¨è—¥é™¸è¼¸å­—ç¬¬001179è™Ÿ | ä¸é†¯èƒºå¡å’¯é…®(åŸæ–™è—¥) | ç²‰æœ« | ä¸æ³°ä¼æ¥­æœ‰é™å…¬å¸ |

æ ¸å‡†é©æ‡‰ç—‡ï¼šé©ç”¨æ–¼1å€‹æœˆå¤§ä»¥ä¸Šå±€éƒ¨ç™²ç™‡ç™¼ä½œç—…äººçš„æ²»ç™‚

## å®‰å…¨æ€§è€ƒé‡
### å¸¸è¦‹å‰¯ä½œç”¨
- å—œç¡ã€é ­æšˆ
- ç–²å€¦
- å™å¿ƒ

### å„ªå‹¢
- å‰¯ä½œç”¨è¼ƒ levetiracetam è¼•å¾®
- è¡Œç‚º/ç²¾ç¥å‰¯ä½œç”¨ç™¼ç”Ÿç‡è¼ƒä½
- ç„¡éœ€åŠ‘é‡èª¿æ•´å³å¯é–‹å§‹ä½¿ç”¨ç›®æ¨™åŠ‘é‡

### è—¥ç‰©äº¤äº’ä½œç”¨
- èˆ‡ CYP2C19 ç›¸é—œä»£è¬
- rifampin å¯èƒ½é™ä½å…¶è¡€ä¸­æ¿ƒåº¦
- é¿å…èˆ‡é…’ç²¾ä½µç”¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAlcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinkin...
- å»ºè­°ï¼šPatients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potential...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**å¡ç“¦** ğŸ”´ Major
- å½±éŸ¿ï¼šå¢å¼·ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶ä½œç”¨
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Depressive Disorder** ğŸŸ¡ Moderate
- Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different A...

**Bronchial Spasm** ğŸŸ¡ Moderate
- Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm an...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**è­‰æ“šç­‰ç´š**ï¼šL3 (å…‰æ•æ„Ÿæ€§ç™²ç™‡çš„è‡¨åºŠç ”ç©¶é–“æ¥æ”¯æŒ)

**å»ºè­°**ï¼š
1. å°æ–¼å…‰æ•æ„Ÿæ€§æˆ–è¦–è¦ºèª˜ç™¼æ€§ç™²ç™‡æ‚£è€…ï¼Œbrivaracetam æ˜¯åˆç†çš„æ²»ç™‚é¸æ“‡
2. å¯è€ƒæ…®å¾ levetiracetam è½‰æ›ï¼Œå°¤å…¶ç•¶æ‚£è€…æœ‰è¡Œç‚ºå‰¯ä½œç”¨æ™‚
3. å»ºè­°åŠ‘é‡ï¼šæˆäººæ¯æ—¥ 50-200 mgï¼Œåˆ†å…©æ¬¡æœç”¨

**ä¸‹ä¸€æ­¥ç ”ç©¶æ–¹å‘**ï¼š
- é‡å°è¦–è¦ºæ€§ç™²ç™‡äºå‹çš„å‰ç»æ€§è‡¨åºŠè©¦é©—
- è©•ä¼° brivaracetam èˆ‡å…¶ä»–ç¬¬ä¸‰ä»£æŠ—ç™²ç™‡è—¥ç‰©åœ¨æ­¤é©æ‡‰ç—‡çš„æ¯”è¼ƒæ•ˆç›Š
- æ”¶é›†çœŸå¯¦ä¸–ç•Œæ•¸æ“šä»¥æ”¯æŒé©æ‡‰ç—‡æ“´å±•


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tyrosine]({{ "/drugs/tyrosine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Thiamine]({{ "/drugs/thiamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Metoprolol]({{ "/drugs/metoprolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Brivaracetamè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/brivaracetam/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_brivaracetam,
  title = {Brivaracetamè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/brivaracetam/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
